TheStreet Readers Make Perfect Predictions in Drug-Approval Contest
BOSTON (TheStreet) -- Congratulations to the 11 perfect winners of TheStreet's Summer FDA Drug Approval Contest.
"Perfect" because each of the winning contestants went 5-0 in predicting correctly the outcome of the following FDA-related events:
1. Onyx Pharmaceuticals (ONXX): FDA advisory panel for the cancer drug carfilzomib on June 20.
2. Arena Pharmaceuticals (ARNA): FDA approval decision for the weight-loss drug lorcaserin on June 27.
3. Vivus (VVUS): FDA approval decision for the weight-loss drug Qnexa on July 20. 4. Amarin (AMRN): FDA approval decision for the prescription fish-oil pill AMR101 on July 26. 5. Onyx: FDA approval decision for carfilzomib on July 27. The 11 winners emerged from a record crowd of 134 entries. [You can read more about the overall predictions from the contest here.] As you read your name, please take a bow and accept my hearty congratulations:The Boss
MarywasavirginLOL
BobH
Seth Lewis
Ken Lauder
Eric
i1Again
Max
Tricia Dineen
Isitabubble That's only 10 names. Who was winner No. 11? Me! Yes, it's true, I actually won my own contest -- without cheating. Thanks again for participating. --Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: tips@thestreet.com. Follow TheStreet on Twitter and become a fan on Facebook.
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
TheStreet Quant Ratings
TRY IT FREENew! $49.95/yr
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Product Features:
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Dividend Stock Advisor
TRY IT FREEJim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV